List of Excipients in Branded Drug WEGOVY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novo Nordisk	WEGOVY	semaglutide	0169-4525	SODIUM CHLORIDE	2029-03-19
Novo Nordisk	WEGOVY	semaglutide	0169-4525	SODIUM PHOSPHATE, DIBASIC, DIHYDRATE	2029-03-19
Novo Nordisk	WEGOVY	semaglutide	0169-4525	WATER	2029-03-19
A-S Medication Solutions	WEGOVY	semaglutide	50090-5824	SODIUM CHLORIDE	2029-03-19

Wegovy Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Wegovy’s excipient profile is simple, established, and commercially accessible. The product uses semaglutide in an aqueous, preservative-containing injection with disodium phosphate dihydrate, propylene glycol, phenol, and water for injection. The strongest commercial opportunities are not likely to come from selling the individual excipients as differentiated products. They are concentrated in qualified pharmaceutical-grade supply, low-endotoxin manufacturing, formulation optimization, device compatibility, fill-finish capacity, and next-generation semaglutide delivery systems.

Novo Nordisk’s formulation creates a relatively low technical barrier for excipient substitution, but regulatory and quality barriers remain significant. Any competing product must match the reference product’s active ingredient, concentration, excipient function, impurity profile, container-closure system, and delivery performance. Semaglutide is a synthetic peptide, not a biologic subject to the U.S. biosimilar pathway. Generic competition would most likely proceed through an abbreviated drug application or another FDA pathway depending on product design and regulatory classification.

What excipients are used in Wegovy injections?

The U.S. Wegovy injection contains four principal inactive ingredients: disodium phosphate dihydrate, propylene glycol, phenol, and water for injection. Hydrochloric acid or sodium hydroxide may be used for pH adjustment. The formulation is supplied in a prefilled single-dose pen.[1]

Component	Function in formulation	Commercial implication
Disodium phosphate dihydrate	Buffering and pH control	Commodity excipient with pharmaceutical-grade and low-bioburden requirements
Propylene glycol	Tonicity and solubility support	Broad supplier base, but injectable-grade quality is essential
Phenol	Preservative	Requires tight control of purity, residual impurities, and container compatibility
Water for injection	Solvent	Requires validated pharmaceutical water systems and microbial control
Hydrochloric acid or sodium hydroxide	pH adjustment	Low-volume but critical process materials

The formulation is a clear, colorless solution administered subcutaneously. Wegovy pens are single-dose products, which reduces the preservative burden associated with multidose vials but does not eliminate the need for phenol in the commercial formulation.[1]

What are the labeled concentrations of Wegovy excipients?

The FDA prescribing information identifies the qualitative excipient composition and gives quantitative amounts per milliliter for the principal inactive ingredients. The formulation contains approximately 1.42 mg/mL disodium phosphate dihydrate, 14 mg/mL propylene glycol, and 5.5 mg/mL phenol, with semaglutide concentration varying by dose presentation.[1]

Wegovy dose strengths are delivered through different pen presentations rather than through a conventional multidose vial strategy. That structure affects fill-finish economics, device qualification, extractables and leachables testing, and supply-chain planning.

Why is Wegovy’s excipient platform commercially attractive?

The commercial opportunity comes from scale and operational complexity rather than excipient novelty. Wegovy has become one of the largest demand drivers in the GLP-1 market, creating procurement pressure across peptide active pharmaceutical ingredient production, sterile filling, pens, cartridges, needles, packaging, and quality-control services.[2]

Which excipients have the strongest supply opportunities?

Pharmaceutical-grade phenol

Phenol is the most strategically sensitive excipient in the formulation because it functions as the preservative and must remain compatible with the peptide, container closure, and delivery device. Opportunities include:

• High-purity phenol for injectable use
• Dual-source qualification
• Low-metal and low-impurity grades
• Long-term supply contracts
• Container-closure compatibility packages
• Stability data supporting alternate suppliers

Phenol suppliers can create greater value through regulatory documentation, change-control discipline, and validated sterile manufacturing than through the underlying chemical itself.

Injectable propylene glycol

Propylene glycol is widely available, but injectable use imposes higher requirements than food, industrial, or oral-pharmaceutical applications. Commercial differentiation can come from:

• ICH impurity documentation
• Control of aldehydes and organic impurities
• Low endotoxin limits
• Consistent water content and density
• Global regulatory files
• Reliable lot-to-lot supply

The opportunity is strongest for suppliers that can support both U.S. and European regulatory submissions.

Disodium phosphate dihydrate

Disodium phosphate dihydrate is a mature buffer excipient with relatively low differentiation. A supplier may still capture value through:

• Sterile or low-bioburden grades
• Tight particle and hydration-state control
• Small-volume injectable packaging
• Supply continuity
• Regional inventory and rapid release testing

This is primarily a scale, quality, and logistics opportunity.

Water for injection and sterile processing

Water for injection is not a conventional third-party excipient opportunity because manufacturers typically produce it onsite. The commercial opportunity is instead linked to:

• Pharmaceutical water systems
• Continuous monitoring
• microbial-control technologies
• sterile compounding
• fill-finish process validation
• high-throughput injectable manufacturing

What formulation properties must a Wegovy competitor match?

A competing semaglutide injection must reproduce the critical quality attributes that determine safety, stability, and dose delivery. These include:

Quality attribute	Why it matters
Semaglutide concentration	Determines delivered dose and pen performance
pH	Affects peptide stability, solubility, and injection tolerability
Osmolality	Affects subcutaneous tolerability
Preservative content	Supports microbiological control and product stability
Peptide purity	Controls related substances and degradation products
Aggregate level	Important for injectable safety and product consistency
Subvisible particles	Relevant to parenteral quality
Container closure integrity	Protects sterility and shelf life
Device delivered volume	Determines dose accuracy
Extractables and leachables	Controls interaction with pen components

The reference formulation’s simplicity may facilitate development of a pharmaceutical equivalent, but formulation sameness alone does not guarantee approval. The applicant must establish pharmaceutical equivalence, bioequivalence where required, manufacturing control, device performance, and acceptable stability.

What formulation patents protect semaglutide and Wegovy?

The commercial protection around Wegovy is broader than its excipient list. Patent rights may cover semaglutide composition, peptide sequence or analog structure, pharmaceutical compositions, dosing regimens, diabetes or obesity treatment methods, manufacturing processes, and delivery systems.

The individual excipients are established substances and generally do not create a meaningful exclusivity barrier by themselves. A formulation patent could still protect a specific combination, concentration range, stability profile, delivery format, or manufacturing process.

When does Wegovy lose exclusivity?

The key U.S. exclusivity risk is tied to Novo Nordisk’s semaglutide patent and related Orange Book-listed rights, not to the expiration of phenol, propylene glycol, or phosphate patents. Publicly reported U.S. semaglutide patent protection has generally been associated with expiry dates extending into approximately 2031, subject to patent-specific term calculations, patent-term adjustment, regulatory exclusivity, and litigation outcomes.[3][4]

The practical timeline is:

Period	Commercial position
Current market period	Novo Nordisk controls the reference product and commercial supply chain
Before core patent expiry	Paragraph IV challenges, settlements, licensing, and litigation determine launch risk
Around core patent expiry	Pharmaceutical-equivalent semaglutide injection competition becomes more credible
After core expiry	Formulation, device, method-of-use, manufacturing, and regulatory barriers remain relevant

Patent expiration must be assessed by individual patent and jurisdiction. A single “Wegovy expiration date” is not sufficient for diligence.

What is the Orange Book status of Wegovy?

Wegovy is approved in the United States under NDA 215256. FDA Orange Book records are the relevant source for listed patents, exclusivity, therapeutic equivalence information, and application status.[3]

The Orange Book analysis should distinguish among:

• Patents covering semaglutide or related composition claims
• Formulation or pharmaceutical-composition claims
• Method-of-use claims for weight management and cardiovascular-risk reduction
• Device or delivery-system rights
• Pediatric exclusivity
• Regulatory exclusivity attached to the NDA
• Patent-term extension or patent-term adjustment

An applicant pursuing an ANDA would need to address each listed patent through certification. A Paragraph IV certification would create potential litigation exposure and could trigger a statutory stay of approval if Novo Nordisk files suit within the applicable period.[5]

Which companies are challenging Wegovy exclusivity?

The competitive field includes generic-drug companies, peptide manufacturers, contract development and manufacturing organizations, and pharmaceutical companies developing alternative GLP-1 products. Publicly disclosed litigation and Paragraph IV activity must be confirmed from FDA records and court dockets before attributing a specific challenge to a company.

The relevant challengers are likely to pursue one or more of four strategies:

1. A pharmaceutical-equivalent semaglutide injection.
2. An alternative semaglutide formulation with a different concentration or device.
3. A compounded or clinically differentiated product outside the conventional ANDA route.
4. A competing GLP-1 or incretin product that avoids semaglutide patent claims.

The first strategy has the greatest direct exposure to Wegovy patents. The third and fourth strategies may avoid some listed patents but create greater clinical, regulatory, and manufacturing requirements.

Does Wegovy have biosimilar risk?

Wegovy does not face conventional biosimilar risk because semaglutide is a chemically synthesized peptide drug rather than a therapeutic protein regulated through the U.S. Public Health Service Act’s biosimilar pathway. A follow-on semaglutide product would more likely be reviewed under the Federal Food, Drug, and Cosmetic Act, including an ANDA where the product qualifies as pharmaceutically equivalent.[6]

The regulatory pathway can become more complex if a competitor changes:

• Concentration
• Route of administration
• Device
• Preservative system
• Dosing schedule
• Release profile
• Peptide sequence or chemical modifications

A changed formulation may require a 505(b)(2) application rather than a conventional ANDA. That route can support differentiated products but may require additional clinical or pharmacokinetic evidence.

What excipient strategies can improve a competing semaglutide product?

Strategy 1: Maintain the reference excipient system

Using disodium phosphate dihydrate, propylene glycol, phenol, and water for injection minimizes formulation-development risk. The main advantages are:

• Greater likelihood of pharmaceutical equivalence
• Lower excipient-change risk
• Easier analytical comparability
• Familiar safety profile
• Stronger basis for a conventional generic strategy

The disadvantage is limited differentiation. The product remains exposed to the same device, manufacturing, stability, and patent issues.

Strategy 2: Develop a preservative-free single-dose formulation

A preservative-free presentation could be commercially attractive if it preserves stability and injection performance. The benefits may include:

• Reduced concern regarding phenol tolerability
• Simplified preservative justification
• Potentially improved positioning for sensitive patients
• More flexibility in container-closure selection

The tradeoff is that a new formulation may require additional studies and could fall outside a straightforward pharmaceutical-equivalence strategy.

Strategy 3: Increase concentration and reduce injection volume

A higher-concentration formulation could support smaller injection volumes, improved device ergonomics, or more efficient shipping. It would require control of:

• Peptide solubility
• Aggregation
• Viscosity
• Injection force
• Dose accuracy
• Subcutaneous tolerability
• Stability during refrigerated and in-use conditions

Concentration-based differentiation may support a 505(b)(2) product and potentially create new formulation claims, but it does not automatically avoid composition or method-of-use patents.

Strategy 4: Create a room-temperature-stable formulation

Reduced cold-chain dependence would have significant commercial value in emerging markets, retail distribution, home delivery, and inventory management. Development priorities would include:

• Chemical degradation control
• Oxidation and deamidation management
• Aggregate suppression
• Container-closure stability
• Transport-shock validation
• In-use stability after removal from refrigeration

A successful room-temperature product could command value through logistics savings even if the underlying excipients remain conventional.

Strategy 5: Develop an oral or alternative-delivery semaglutide product

Oral semaglutide and other noninjectable formats offer the largest potential commercial differentiation. The formulation challenge is substantially greater because the peptide must survive gastrointestinal conditions and achieve adequate absorption.

Potential technologies include:

• Permeation enhancers
• Enteric protection
• Mucoadhesive systems
• Nanoparticle or lipid-based delivery
• Buccal or sublingual systems
• Long-acting depot delivery

These products would likely require substantial clinical and regulatory investment. Their value would come from adherence, patient preference, and expanded access rather than from excipient cost reduction.

What manufacturing and IP barriers affect excipient suppliers?

Excipient suppliers face lower patent risk than semaglutide API suppliers, but they face meaningful qualification barriers. A supplier change can require comparability testing, process validation, stability assessment, regulatory notification, and sometimes approval before implementation.

Key barriers include:

• FDA-acceptable manufacturing sites
• GMP inspection history
• Pharmacopeial compliance
• Low-endotoxin control
• Traceability of raw materials
• Change-notification commitments
• Global regulatory support
• Capacity reservations
• Validated packaging and shipping conditions

For phenol and injectable propylene glycol, the best commercial position is likely a qualified, multi-region supply platform rather than a new chemical entity.

How does Wegovy compare with competing GLP-1 products?

Product	Active ingredient	Primary delivery	Excipient opportunity
Wegovy	Semaglutide	Weekly subcutaneous injection	Injectable supply, pen systems, stability, alternative delivery
Ozempic	Semaglutide	Weekly subcutaneous injection	Shared semaglutide and device-related ecosystem
Mounjaro	Tirzepatide	Weekly subcutaneous injection	Peptide stability, high-volume sterile manufacturing
Zepbound	Tirzepatide	Weekly subcutaneous injection	Similar device and formulation supply opportunities
Saxenda	Liraglutide	Daily subcutaneous injection	Lower-growth legacy GLP-1 platform
Rybelsus	Semaglutide	Daily oral tablet	Oral absorption and excipient delivery technologies

Wegovy and Ozempic create the largest shared semaglutide opportunity, while Mounjaro and Zepbound expand demand for peptide manufacturing and injectable delivery capacity. Rybelsus provides the most relevant benchmark for oral semaglutide formulation strategy.

What is the revenue exposure to Wegovy supply constraints?

Novo Nordisk has reported rapid growth in obesity-care demand and has invested heavily in manufacturing expansion for semaglutide products.[2] The financial exposure is concentrated in the active ingredient, sterile fill-finish, prefilled pens, and needles. Excipient shortages alone are less likely to be the primary constraint because the listed excipients are widely manufactured chemicals.

The commercial impact of an excipient disruption can still be material if:

• The affected grade is sole-sourced
• A supplier change requires regulatory review
• The material is embedded in a validated sterile process
• The formulation has narrow stability margins
• Pen assembly cannot be requalified quickly
• Global sites use different approved excipient sources

Supplier contracts that include technical transfer, backup manufacturing, and regulatory-change support are more valuable than spot-market excipient supply.

What generic launch scenarios exist for Wegovy?

Early Paragraph IV launch

A challenger files an ANDA with a Paragraph IV certification and litigates before patent expiry. This approach offers a possible first-launch advantage but carries substantial invalidity, noninfringement, and damages risk.

At-risk launch

A company launches before final resolution. This creates substantial exposure to injunctive relief and damages and is generally viable only with a strong patent position and sufficient balance-sheet capacity.

Post-expiry launch

A generic enters after core patent expiry or settlement-defined entry. This reduces litigation risk but compresses differentiation and price.

505(b)(2) differentiated launch

A company launches a higher-concentration, preservative-free, room-temperature-stable, or alternative-delivery product. The product may avoid some ANDA constraints but requires a stronger clinical and regulatory package.

Key Takeaways

• Wegovy uses disodium phosphate dihydrate, propylene glycol, phenol, and water for injection.
• The individual excipients are mature products; the main value lies in injectable-grade quality, supply reliability, and regulatory support.
• Phenol and injectable propylene glycol offer the clearest specialty-supplier opportunities.
• The largest commercial opportunities are higher-concentration injections, room-temperature stability, preservative-free presentations, and oral or alternative semaglutide delivery.
• Semaglutide is not a conventional biosimilar product. Follow-on competition would generally involve ANDA or 505(b)(2) strategies.
• Core semaglutide patent protection has been publicly associated with U.S. expiry dates extending to approximately 2031, while later formulation, device, method-of-use, and manufacturing rights may affect entry.
• The primary supply-chain bottlenecks are semaglutide API, sterile fill-finish, pens, and device capacity, not the commodity excipients alone.
• A successful excipient strategy must combine formulation performance with dual sourcing, GMP documentation, change control, and container-device compatibility.

FAQs

Can a supplier patent phenol or propylene glycol in Wegovy?

The underlying excipients are established substances. Commercially meaningful protection would more likely attach to a specific pharmaceutical composition, impurity profile, stabilization system, manufacturing process, or delivery device than to phenol or propylene glycol themselves.

Would removing phenol create a non-infringing Wegovy alternative?

Not necessarily. Removing or replacing phenol could avoid a narrow formulation claim, but it would not by itself avoid patents covering semaglutide, pharmaceutical compositions, dosing methods, manufacturing, or device systems.

Is a higher-concentration semaglutide injection automatically a 505(b)(2) product?

No. The pathway depends on the product’s relationship to the reference drug, including formulation, dosage form, strength, device, and evidence required by FDA. A higher concentration may require a different regulatory strategy, but concentration alone does not determine the pathway.

Which excipient has the greatest effect on Wegovy stability?

The answer depends on the degradation mechanism and product design. The buffer, solvent, preservative, peptide concentration, pH, oxygen exposure, and container closure operate together. Phenol is particularly important for preservative performance and compatibility, while pH and phosphate control affect peptide stability.

Can a room-temperature-stable semaglutide product command premium pricing?

It could create commercial value through lower cold-chain costs, broader distribution, and improved patient convenience. Premium pricing would depend on clinical differentiation, payer coverage, device performance, and the extent to which the product avoids or remains exposed to Novo Nordisk’s patent estate.

References

1. U.S. Food and Drug Administration. (2024). Wegovy (semaglutide) injection prescribing information. Novo Nordisk A/S.

2. Novo Nordisk A/S. (2024). Annual report 2023. Novo Nordisk.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information. https://www.uspto.gov/

5. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Refuse-to-receive standards and Paragraph IV certifications. https://www.fda.gov/

6. U.S. Food and Drug Administration. (2023). Regulatory considerations for follow-on protein products and peptide drug products. https://www.fda.gov/